Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study
Status PubMed-not-MEDLINE Language English Country Canada Media electronic
Document type Journal Article
PubMed
30888333
PubMed Central
PMC6444213
DOI
10.2196/11868
PII: v8i3e11868
Knihovny.cz E-resources
- Keywords
- GWAS, candidate genes, childhood cancer survivors, cisplatin, genetics, hearing loss, ototoxicity, polymorphisms,
- Publication type
- Journal Article MeSH
BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood cancer treatment have been identified, the individual variability in toxicity of adverse effects after similar treatment between childhood cancer patients suggests a role for genetic susceptibility. Currently, 12 candidate gene approach studies have been performed to identify polymorphisms predisposing to platinum-induced ototoxicity in children being treated for cancer. However, results were inconsistent and most studies were underpowered and/or lacked replication. OBJECTIVE: We describe the design of the PanCareLIFE consortium's work packages that address the genetic susceptibility of platinum-induced ototoxicity. METHODS: As a part of the PanCareLIFE study within the framework of the PanCare consortium, we addressed genetic susceptibility of treatment-induced ototoxicity during and after childhood cancer treatment in a large European cohort by a candidate gene approach and a genome-wide association screening. RESULTS: This study included 1124 survivors treated with cisplatin, carboplatin, or cranial radiotherapy for childhood cancer, resulting in the largest clinical European cohort assembled for this late effect to date. Within this large cohort we defined a group of 598 cisplatin-treated childhood cancer patients not confounded by cranial radiotherapy. The PanCareLIFE initiative provided, for the first time, a unique opportunity to confirm already identified determinants for hearing impairment during childhood cancer using a candidate gene approach and set up the first international genome-wide association study of cisplatin-induced direct ototoxicity in childhood cancer patients to identify novel allelic variants. Results will be validated in an independent replication cohort. Patient recruitment started in January 2015 and final inclusion was October 2017. We are currently performing the analyses and the first results are expected by the end of 2019 or the beginning of 2020. CONCLUSIONS: Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the development of prevention strategies. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/11868.
Boyne Research Institute Drogheda Ireland
Danish Cancer Society Research Center Copenhagen Denmark
Department of Clinical Medicine Faculty of Health Aarhus University Aarhus Denmark
Department of Internal Medicine Erasmus Medical Center Rotterdam Netherlands
Department of Neurooncology Institute Giannina Gaslini Genova Italy
Department of Paediatric Oncology University Hospital Brno Masaryk University Brno Czech Republic
Department of Pediatric Hemato Oncology Motol University Hospital Prague Prague Czech Republic
Department of Pediatric Hematology and Oncology VU Medical Center Amsterdam Netherlands
Department of Pediatric Oncology Academic Medical Center Amsterdam Amsterdam Netherlands
Department of Pediatric Oncology University Hospital for Children and Adolescents Luebeck Germany
Department of Pediatrics Aarhus University Hospital Aarhus Denmark
Department of Phoniatrics and Pedaudiology University of Münster Muenster Germany
Institute of Social and Preventive Medicine University of Bern Bern Switzerland
Princess Maxima Center for Pediatric Oncology Utrecht Netherlands
St Anne's University Hospital Brno International Clinical Research Center Brno Czech Republic
See more in PubMed
Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010 Jun;36(4):277–285. doi: 10.1016/j.ctrv.2010.02.003.S0305-7372(10)00023-X PubMed DOI
Geenen M, Cardous-Ubbink M, Kremer L, van den Bos C, van der Pal H, Heinen R, Jaspers M, Koning C, Oldenburger F, Langeveld N, Hart A, Bakker P, Caron H, van Leeuwen F. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007 Jun 27;297(24):2705–2715. doi: 10.1001/jama.297.24.2705.297/24/2705 PubMed DOI
Oeffinger K, Mertens A, Sklar C, Kawashima T, Hudson M, Meadows A, Friedman D, Marina N, Hobbie W, Kadan-Lottick N, Schwartz C, Leisenring W, Robison L, Childhood Cancer Survivor Study Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006 Oct 12;355(15):1572–1582. doi: 10.1056/NEJMsa060185.355/15/1572 PubMed DOI
Landier W. Ototoxicity and cancer therapy. Cancer. 2016 Jun 01;122(11):1647–1658. doi: 10.1002/cncr.29779. doi: 10.1002/cncr.29779. PubMed DOI
Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004 Oct;26(10):649–655. doi: 10.1097/01.mph.0000141348.62532.73.00043426-200410000-00007 PubMed DOI
Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005 Dec 01;23(34):8588–8596. doi: 10.1200/JCO.2004.00.5355.23/34/8588 PubMed DOI
Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010 Apr;125(4):e938–E950. doi: 10.1542/peds.2009-1597. peds.2009-1597 PubMed DOI PMC
Al-Khatib T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol. 2010 Aug;74(8):913–919. doi: 10.1016/j.ijporl.2010.05.011.S0165-5876(10)00221-1 PubMed DOI
Weiss A, Sommer G, Kasteler R, Scheinemann K, Grotzer M, Kompis M, Kuehni C, Swiss Pediatric Oncology Group (SPOG) Long-term auditory complications after childhood cancer: a report from the Swiss Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2017 Dec;64(2):364–373. doi: 10.1002/pbc.26212. PubMed DOI
Laverdière C, Cheung N, Kushner B, Kramer K, Modak S, LaQuaglia M, Wolden S, Ness K, Gurney J, Sklar C. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005 Sep;45(3):324–332. doi: 10.1002/pbc.20331. PubMed DOI
Clemens E, de Vries A, Pluijm S, Am Zehnhoff-Dinnesen A, Tissing W, Loonen J, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer L, van der Pal H, van Grotel M, van den Heuvel-Eibrink M. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer. 2016 Dec;69:77–85. doi: 10.1016/j.ejca.2016.09.023.S0959-8049(16)32469-8 PubMed DOI
Lanvers-Kaminsky C, Zehnhoff-Dinnesen A, Parfitt R, Ciarimboli G. Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies. Clin Pharmacol Ther. 2017 Dec;101(4):491–500. doi: 10.1002/cpt.603. PubMed DOI
Bess F, Dodd-Murphy J, Parker R. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998 Oct;19(5):339–354. PubMed
Whelan K, Stratton K, Kawashima T, Leisenring W, Hayashi S, Waterbor J, Blatt J, Sklar C, Packer R, Mitby P, Robison L, Mertens A. Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2011 Jul 15;57(1):126–134. doi: 10.1002/pbc.23025. PubMed DOI PMC
Gurney J, Tersak J, Ness K, Landier W, Matthay K, Schmidt M, Children's Oncology Group Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics. 2007 Nov;120(5):e1229–e1236. doi: 10.1542/peds.2007-0178.120/5/e1229 PubMed DOI
Freyer D, Chen L, Krailo M, Knight K, Villaluna D, Bliss B, Pollock B, Ramdas J, Lange B, Van Hoff D, Van Soelen M, Wiernikowski J, Neuwelt E, Sung L. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 Dec;18(1):63–74. doi: 10.1016/S1470-2045(16)30625-8. S1470-2045(16)30625-8 PubMed DOI PMC
Weissenstein A, Deuster D, Knief A, am Zehnhoff-Dinnesen A, Schmidt C. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):131–136. doi: 10.1016/j.ijporl.2011.10.020.S0165-5876(11)00556-8 PubMed DOI
Knight K, Kraemer D, Winter C, Neuwelt E. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007 Apr 01;25(10):1190–1195. doi: 10.1200/JCO.2006.07.9723.25/10/1190 PubMed DOI
Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, am Zehnhoff-Dinnesen A. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 2008 Feb;8(1):23–28. doi: 10.1038/sj.tpj.6500455.6500455 PubMed DOI
PanCareLIFE: Pan-European network for care of survivors after childhood and adolescent cancer. [2019-01-22]. http://www.pancarelife.eu/
Pan-European network for care of survivors after childhood and adolescent cancer. [2019-01-22]. https://www.pancare.eu/en/
Clemens E, de Vries A, am Zehnhoff-Dinnesen A, Tissing W, Loonen J, Pluijm S, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer L, van der Pal H, Neggers S, van Grotel M, van den Heuvel-Eibrink M. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatr Hematol Oncol. 2017 Mar;34(2):120–129. doi: 10.1080/08880018.2017.1323985. PubMed DOI
Lanvers-Kaminsky C, Krefeld B, Dinnesen A, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck A, Boos J. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006 Aug;47(2):183–193. doi: 10.1002/pbc.20673. PubMed DOI
Schmidt C, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG. [The Muenster classification of high frequency hearing loss following cisplatin chemotherapy] HNO. 2007 Apr;55(4):299–306. doi: 10.1007/s00106-005-1368-1. PubMed DOI
Bass J, Huang J, Onar-Thomas A, Chang K, Bhagat S, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath J, McCowage G, Cohn R, Fisher M, Robinson G, Broniscer A, Gajjar A, Gurney J. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014 Apr;61(4):601–605. doi: 10.1002/pbc.24830. PubMed DOI PMC
Brock P, Knight K, Freyer D, Campbell K, Steyger P, Blakley B, Rassekh S, Chang K, Fligor B, Rajput K, Sullivan M, Neuwelt E. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012 Jul 01;30(19):2408–2417. doi: 10.1200/JCO.2011.39.1110. JCO.2011.39.1110 PubMed DOI PMC
van der Kooi A, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, van den Berg M, Berger C, Calaminus G, Dirksen U, Winther J, Fosså S, Grabow D, Haupt R, Kaiser M, Kepak T, Kremer L, Kruseova J, Modan-Moses D, Ranft A, Spix C, Kaatsch P, Laven J, van Dulmen-den Broeder E, Uitterlinden A, van den Heuvel-Eibrink M, PanCareLIFE Consortium Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer. 2018 Sep 26;18(1):930. doi: 10.1186/s12885-018-4834-3. 10.1186/s12885-018-4834-3 PubMed DOI PMC
Brown A, Lupo P, Okcu M, Lau C, Rednam S, Scheurer M. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med. 2015 Nov;4(11):1679–1686. doi: 10.1002/cam4.516. doi: 10.1002/cam4.516. PubMed DOI PMC
Carleton B, Ross C, Bhavsar A, Amstutz U, Pussegoda K, Visscher H, Lee J, Brooks B, Rassekh S, Dubé M, Hayden M. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219.clpt2013219 PubMed DOI
Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, Pakakasama S, Hongeng S. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol. 2013 May;35(4):e138–e143. doi: 10.1097/MPH.0b013e3182707fc5. PubMed DOI
Drögemöller B, Monzon J, Bhavsar A, Borrie A, Brooks B, Wright G, Liu G, Renouf D, Kollmannsberger C, Bedard P, Aminkeng F, Amstutz U, Hildebrand C, Gunaretnam E, Critchley C, Chen Z, Brunham L, Hayden M, Ross C, Gelmon K, Carleton B. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017 Nov 01;3(11):1558–1562. doi: 10.1001/jamaoncol.2017.0502. 2621990 PubMed DOI PMC
Hagleitner M, Coenen M, Patino-Garcia A, de Bont E, Gonzalez-Neira A, Vos H, van Leeuwen F, Gelderblom H, Hoogerbrugge P, Guchelaar H, Te Loo M. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One. 2014;9(12):e115869. doi: 10.1371/journal.pone.0115869. PONE-D-14-08447 PubMed DOI PMC
Lanvers-Kaminsky C, Sprowl J, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen R, Boos J, Jürgens H, Am Zehnhoff-Dinnesen A, Sparreboom A, Ciarimboli G. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics. 2015;16(4):323–332. doi: 10.2217/pgs.14.182. PubMed DOI PMC
Rednam S, Scheurer M, Adesina A, Lau C, Okcu M. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer. 2013 Apr;60(4):593–598. doi: 10.1002/pbc.24366. PubMed DOI PMC
Ross C, Katzov-Eckert H, Dubé M, Brooks B, Rassekh S, Barhdadi A, Feroz-Zada Y, Visscher H, Brown A, Rieder M, Rogers P, Phillips M, Carleton B, Hayden M, CPNDS Consortium Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009 Dec;41(12):1345–1349. doi: 10.1038/ng.478.ng.478 PubMed DOI
Spracklen T, Vorster A, Ramma L, Dalvie S, Ramesar R. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin. Pharmacogenomics J. 2017 Dec;17(6):515–520. doi: 10.1038/tpj.2016.52.tpj201652 PubMed DOI
Spracklen T, Whitehorn H, Vorster A, Ramma L, Dalvie S, Ramesar R. Genetic variation in Otos is associated with cisplatin-induced ototoxicity. Pharmacogenomics. 2014 Sep;15(13):1667–1676. doi: 10.2217/pgs.14.112. PubMed DOI
Vos H, Guchelaar H, Gelderblom H, de Bont E, Kremer L, Naber A, Hakobjan M, van der Graaf W, Coenen M, te Loo D. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. Pharmacogenet Genomics. 2016 May;26(5):243–247. doi: 10.1097/FPC.0000000000000212. PubMed DOI
Xu H, Robinson G, Huang J, Lim J, Zhang H, Bass J, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart C, Yang J. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015 Mar;47(3):263–266. doi: 10.1038/ng.3217. ng.3217 PubMed DOI PMC
Yang J, Lim J, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead E, Robinson G, Evans W, Pappo A, Zuo J, Relling M, Onar-Thomas A, Gajjar A, Stewart C. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther. 2013 Aug;94(2):252–259. doi: 10.1038/clpt.2013.121. clpt2013121 PubMed DOI PMC
Thiesen S, Yin P, Jorgensen A, Zhang J, Manzo V, McEvoy L, Barton C, Picton S, Bailey S, Brock P, Vyas H, Walker D, Makin G, Bandi S, Pizer B, Hawcutt D, Pirmohamed M. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenet Genomics. 2017 Dec;27(6):213–222. doi: 10.1097/FPC.0000000000000281. PubMed DOI PMC
Pussegoda K, Ross C, Visscher H, Yazdanpanah M, Brooks B, Rassekh S, Zada Y, Dubé M, Carleton B, Hayden M, CPNDS Consortium Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013 Aug;94(2):243–251. doi: 10.1038/clpt.2013.80. clpt201380 PubMed DOI PMC
Drögemöller B, Brooks B, Critchley C, Monzon J, Wright G, Liu G, Renouf D, Kollmannsberger C, Bedard P, Hayden M, Gelmon K, Carleton B, Ross C. Further investigation of the role of and pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clin Cancer Res. 2018 Apr 15;24(8):1866–1871. doi: 10.1158/1078-0432.CCR-17-2810.1078-0432.CCR-17-2810 PubMed DOI
Genetic Laboratory Erasmus MC Rotterdam. [2019-01-22]. http://www.glimdna.org/
Infinium Global Screening Array. [2019-01-22]. https://www.illumina.com/products/by-type/microarray-kits/infinium-global-screening.html .
Abraham G, Inouye M. Fast principal component analysis of large-scale genome-wide data. PLoS One. 2014;9(4):e93766. doi: 10.1371/journal.pone.0093766. PONE-D-14-04258 PubMed DOI PMC
Michigan Imputation Server. [2019-01-22]. https://imputationserver.sph.umich.edu/index.html .
The Haplotype Reference Consortium. [2019-01-22]. http://www.haplotype-reference-consortium.org/
Ikram M, Brusselle G, Murad S, van Duijn C, Franco O, Goedegebure A, Klaver C, Nijsten T, Peeters R, Stricker B, Tiemeier H, Uitterlinden A, Vernooij M, Hofman A. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017 Dec;32(9):807–850. doi: 10.1007/s10654-017-0321-4. 10.1007/s10654-017-0321-4 PubMed DOI PMC
Medina-Gomez C, Felix J, Estrada K, Peters M, Herrera L, Kruithof C, Duijts L, Hofman A, van Duijn C, Uitterlinden A, Jaddoe V, Rivadeneira F. Challenges in conducting genome-wide association studies in highly admixed multi-ethnic populations: the Generation R Study. Eur J Epidemiol. 2015 Apr;30(4):317–330. doi: 10.1007/s10654-015-9998-4. PubMed DOI PMC
Hua C, Bass J, Khan R, Kun L, Merchant T. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys. 2008 Nov 01;72(3):892–899. doi: 10.1016/j.ijrobp.2008.01.050.S0360-3016(08)00229-0 PubMed DOI
Williams G, Kun L, Thompson J, Gould H, Stocks R. Hearing loss as a late complication of radiotherapy in children with brain tumors. Ann Otol Rhinol Laryngol. 2005 Apr;114(4):328–331. doi: 10.1177/000348940511400413. PubMed DOI
Brock P, Bellman S, Yeomans E, Pinkerton C, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295–300. PubMed
Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines] American Speech-Language-Hearing Association; 1994. [2019-01-22]. https://www.asha.org/policy/GL1994-00003.htm .
Chang K, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010 Apr 01;28(10):1788–1795. doi: 10.1200/JCO.2009.24.4228.JCO.2009.24.4228 PubMed DOI
Waissbluth S, Peleva E, Daniel S. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1187–1196. doi: 10.1007/s00405-016-4117-z.10.1007/s00405-016-4117-z PubMed DOI
Knight K, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer D, Lindenfeld L, Meza J, Neuwelt E, Pollock B, Sung L. Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): a report from the children's oncology group. J Clin Oncol. 2017 Feb;35(4):440–445. doi: 10.1200/JCO.2016.69.2319. 10.1200/JCO.2016.69.2319 PubMed DOI PMC
Lafay-Cousin L, Purdy E, Huang A, Cushing S, Papaioannou V, Nettel-Aguirre A, Bouffet E. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr Blood Cancer. 2013 Feb;60(2):287–292. doi: 10.1002/pbc.24307. PubMed DOI
Weiss A, Kuonen R, Brockmeier H, Grotzer M, Candreia C, Maire R, Senn P, Stieger C, Rosenfeld J, Veraguth D, Kompis M, Scheinemann K, Kuehni C, Swiss Pediatric Oncology Group (SPOG) Audiological monitoring in Swiss childhood cancer patients. Pediatr Blood Cancer. 2018 Mar;65(3) doi: 10.1002/pbc.26877. PubMed DOI
